First Time Loading...

Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 1.43 USD -3.38% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

XGN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely dif... [ Read More ]

The intrinsic value of one XGN stock under the Base Case scenario is 9.69 USD. Compared to the current market price of 1.43 USD, Exagen Inc is Undervalued by 85%.

Key Points:
XGN Intrinsic Value
Base Case
9.69 USD
Undervaluation 85%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Exagen Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling XGN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Exagen Inc

Provide an overview of the primary business activities
of Exagen Inc.

What unique competitive advantages
does Exagen Inc hold over its rivals?

What risks and challenges
does Exagen Inc face in the near future?

Has there been any significant insider trading activity
in Exagen Inc recently?

Summarize the latest earnings call
of Exagen Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Exagen Inc.

Provide P/S
for Exagen Inc.

Provide P/E
for Exagen Inc.

Provide P/OCF
for Exagen Inc.

Provide P/FCFE
for Exagen Inc.

Provide P/B
for Exagen Inc.

Provide EV/S
for Exagen Inc.

Provide EV/GP
for Exagen Inc.

Provide EV/EBITDA
for Exagen Inc.

Provide EV/EBIT
for Exagen Inc.

Provide EV/OCF
for Exagen Inc.

Provide EV/FCFF
for Exagen Inc.

Provide EV/IC
for Exagen Inc.

Show me price targets
for Exagen Inc made by professional analysts.

What are the Revenue projections
for Exagen Inc?

How accurate were the past Revenue estimates
for Exagen Inc?

What are the Net Income projections
for Exagen Inc?

How accurate were the past Net Income estimates
for Exagen Inc?

What are the EPS projections
for Exagen Inc?

How accurate were the past EPS estimates
for Exagen Inc?

What are the EBIT projections
for Exagen Inc?

How accurate were the past EBIT estimates
for Exagen Inc?

Compare the revenue forecasts
for Exagen Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Exagen Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Exagen Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Exagen Inc compared to its peers.

Compare the P/E ratios
of Exagen Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Exagen Inc with its peers.

Analyze the financial leverage
of Exagen Inc compared to its main competitors.

Show all profitability ratios
for Exagen Inc.

Provide ROE
for Exagen Inc.

Provide ROA
for Exagen Inc.

Provide ROIC
for Exagen Inc.

Provide ROCE
for Exagen Inc.

Provide Gross Margin
for Exagen Inc.

Provide Operating Margin
for Exagen Inc.

Provide Net Margin
for Exagen Inc.

Provide FCF Margin
for Exagen Inc.

Show all solvency ratios
for Exagen Inc.

Provide D/E Ratio
for Exagen Inc.

Provide D/A Ratio
for Exagen Inc.

Provide Interest Coverage Ratio
for Exagen Inc.

Provide Altman Z-Score Ratio
for Exagen Inc.

Provide Quick Ratio
for Exagen Inc.

Provide Current Ratio
for Exagen Inc.

Provide Cash Ratio
for Exagen Inc.

What is the historical Revenue growth
over the last 5 years for Exagen Inc?

What is the historical Net Income growth
over the last 5 years for Exagen Inc?

What is the current Free Cash Flow
of Exagen Inc?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
Exagen Inc

Current Assets 47.8m
Cash & Short-Term Investments 36.5m
Receivables 6.6m
Other Current Assets 4.8m
Non-Current Assets 9.1m
PP&E 8.5m
Other Non-Current Assets 616k
Current Liabilities 11.9m
Accounts Payable 3.1m
Accrued Liabilities 7.7m
Other Current Liabilities 1.1m
Non-Current Liabilities 22.3m
Long-Term Debt 19.6m
Other Non-Current Liabilities 2.8m
Efficiency

Earnings Waterfall
Exagen Inc

Revenue
52.5m USD
Cost of Revenue
-23.1m USD
Gross Profit
29.5m USD
Operating Expenses
-53.8m USD
Operating Income
-24.3m USD
Other Expenses
648k USD
Net Income
-23.7m USD

Free Cash Flow Analysis
Exagen Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

XGN Profitability Score
Profitability Due Diligence

Exagen Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
21/100
Profitability
Score

Exagen Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

XGN Solvency Score
Solvency Due Diligence

Exagen Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
41/100
Solvency
Score

Exagen Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XGN Price Targets Summary
Exagen Inc

Wall Street analysts forecast XGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XGN is 5.61 USD with a low forecast of 5.05 USD and a high forecast of 7.35 USD.

Lowest
Price Target
5.05 USD
253% Upside
Average
Price Target
5.61 USD
292% Upside
Highest
Price Target
7.35 USD
414% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

XGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

XGN Price
Exagen Inc

1M 1M
-19%
6M 6M
-22%
1Y 1Y
-43%
3Y 3Y
-91%
5Y 5Y
-92%
10Y 10Y
-92%
Annual Price Range
1.43
52w Low
1.42
52w High
3.48
Price Metrics
Average Annual Return -26.24%
Standard Deviation of Annual Returns 49.8%
Max Drawdown -95%
Shares Statistics
Market Capitalization 24.4m USD
Shares Outstanding 17 235 800
Percentage of Shares Shorted 0.29%

XGN Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Exagen Inc Logo
Exagen Inc

Country

United States of America

Industry

Biotechnology

Market Cap

24.4m USD

Dividend Yield

0%

Description

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 219 full-time employees. The company went IPO on 2019-09-19. The firm offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The firm develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The firm's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

Contact

CALIFORNIA
Vista
1261 Liberty Way Ste C
+18884521522.0
http://www.exagen.com

IPO

2019-09-19

Employees

219

Officers

Executive Chairman of the Board of Directors
Dr. Tina S. Nova Ph.D.
CEO, President & Director
Mr. John Aballi
CFO & Corporate Secretary
Mr. Kamal Adawi M.S., MBA
Investors Relations Officer
Ryan Douglas
Senior Vice President of Sales and Marketing
Mr. John Wegener
Chief Innovation Officer & Member of Rheumatoid Arthritis Scientific Advisory Board
Dr. Andrew L. Concoff FACR, M.D.
Show More
Chief Medical Officer
Dr. Michael I. Nerenberg M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one XGN stock?

The intrinsic value of one XGN stock under the Base Case scenario is 9.69 USD.

Is XGN stock undervalued or overvalued?

Compared to the current market price of 1.43 USD, Exagen Inc is Undervalued by 85%.